Document:

Exhibit
10.26

 

Consulting
Agreement

Medical
Advisory Agreement: Field of Orthopedic Surgery

ADVISORY BOARD AGREEMENT

Director
of Medical Practice Strategy / Director Medical (“DM”)

NON AFFILIATE / NON FIDUCIARY CONSULTING POSITION

 

 

Tauriga
Sciences Inc.

4
Nancy Court, Suite # 4

Wappingers Falls, NY 12590

 

TITLE
FOR Dr. Craig Loucks: ADVISORY BOARD (Medical)

 

AGREEMENT
DURATION: 24 Months (May 15, 2021 thru May 14, 2023)

 

This
Comprehensive Consulting Agreement (this “Agreement”) is made effective as of May 15, 2021 by and between Tauriga
Sciences Inc. (OTCQB: TAUG) (“TAUG” or “Tauriga”), a Florida corporation, with a principal
address of 4 Nancy Court, Suite # 4 / Wappingers Falls, NY 12590 and Dr. Craig Loucks (“Dr. Loucks” or “Dr.
L” or “DM”), an individual, with its mailing address at 145 Inverness Drive E., Suite # 220 //
Englewood, Colorado 80112 .

 

W
I T N E S S E T H:

 

WHEREAS,
Tauriga is engaged in the manufacture, sale and distribution of a CBD Infused Chewing Gum Product Line (branded as Tauri-GumTM)
(the “Products”) initially focusing on the Medical Practice Business Segment (Additionally: Medical/Orthopedists);

 

WHEREAS,
Tauriga is the owner or exclusive United States licensee, with authority to sublicense, of the trademarks listed on Exhibit A hereto,
and all service marks, designs, logos, trade names, advertising, commercial symbols and slogans used in connection with Products (as
defined below) (collectively or separately, the “Trademarks”) for the Products and/or such other products that may
become subject to this Agreement;

 

    	 

     

    

 

WHEREAS,
Dr. L is engaged in the field of Orthopedic Surgery in Colorado and has relationships with numerous medical practices, physicians, and
other helpful contacts – across the United States of America.

 

WHEREAS,
Tauriga and Dr. L have agreed that the Date of Execution shall be defined as: May 15 2021.

 

In
consideration of the matters described above, and of the mutual benefits and obligations set forth in this agreement, the parties agree
as follows:

 

 

 

I.
INTRODUCTIONS TO MEDICAL PRACTICES.

 

THREE
DISTINCT CBD Infused Chewing Gum Flavors - Tauri-GumTM Flavors (Mint, Blood Orange, Pomegranate) and Plant Based Gummy Product,
branded as: Tauri-Gummies. As recently disclosed, Two CBG Infused Chewing Gum Flavor – Tauri-GumTM (Peach-Lemon and Black
Currant), and One Immune Booster version (Pear Bellini).

 

    	 

     

    

 

 

 

I.
TAURIGA OBLIGATIONS.

 

1.
Marketing Support. Dr. L. and Tauriga shall from time to time during the term of this Agreement, no less frequently as annually,
mutually determine promotional and marketing programs

 

2.
Materials to be Furnished by Tauriga.  Tauriga shall furnish to Dr. L. technical and sales promotional materials,
brochures, bulletins, and specification data on Products from time to time. Such materials will be furnished in reasonable
quantities at no cost to Dr. L.

 

    	 

     

    

 

3.
Intellectual Property. During the Term, Tauriga hereby grants to Dr. L. a limited, non-transferrable, non-exclusive license to use
the Trademarks and Other IP Tauriga shall fill promptly all orders from DM for Products and for other items to be provided by Tauriga
hereunder.

 

4.
Tauriga shall promptly pay or credit to Dr. L.’s account, when due, not less frequently than monthly, all approved and verified
credits, discounts, allowances, incentive payments, bill backs or other reimbursements due DM pursuant to any program to which the parties
may agree.

 

5.
Tauriga represents and warrants that:

 

(a)
the Products upon delivery to Dr. L.,

 

(i)
shall be pure and wholesome, fit for human use, merchantable and free from all defects,

 

(ii)
shall, in all instances, comply with all applicable Federal, state or local laws and regulations, in all respects, including without
limitation, beverage quality, labeling, identity, quantity, packaging, and returnable container or deposit requirements;

 

(iii)
shall not be adulterated and misbranded within the meaning of those terms under the Federal Food, Drug and Cosmetic Act, as amended,
and shall not be an article or articles which may not, under the provisions, of said Act, be introduced into interstate commerce;

 

(iv)
shall not be adulterated or misbranded within the meaning of the Federal Insecticide, Fungicide, and Rodenticide Act, the Federal Hazardous
Substances Act, or any applicable state act or any other applicable Federal, state, or local law or regulation; and

 

(v)
when delivered to Dr. L., shall have a remaining shelf life of not less than twelve (12) months, the expiration of which
shall be clearly marked on the outside of all cartons and pallets;

 

(b)
it is the owner or exclusive U.S. licensee of the Trademarks and Other IP, that it has the right to license the Trademarks and Other
IP to Dr. L. throughout the Term of this Agreement, and that Dr. L.’s use of the Trademarks and Other IP as provided by this Agreement
will not infringe or violate the rights of any third party; and

 

(c)
it is free to enter into this Agreement and is not under any obligation, written or otherwise, to any other party which would prevent
Tauriga from complying with all the terms and conditions of this Agreement

 

II.
CONSIDERATION. In addition to any other amounts due to Dr. L. hereunder, Tauriga shall pay and/or deliver the following:

 

1.
Restricted Stock. Tauriga shall issue and deliver 1,100,000 shares of TAUG common stock to Dr. L., fully paid for and vested upon
the execution of this Agreement. The Rule 144 date, shall commence on May 15, 2021

 

2.
CASH Payments: $4,000 Each Quarter (for duration of Agreement / which commenced during 1st Fiscal Quarter 2022) . . .
8 Total Payments (1st Payment has been paid as of June 10, 2021)

 

    	 

     

    

 

III.
TERMINATION

 

1.
Subject to Section VI(5) below, either party shall have the right to terminate this Agreement upon the other party’s failure to
perform any of its material obligations contained in this Agreement, provided however that the non- breaching party shall first give
notice to the breaching party (within ten (10) days of knowledge of the breach) of each such failure and the breaching party shall have
twenty (20) days after receipt of each such notice to cure such failure. If such breach is not cured within such period, the non-breaching
party may terminate this Agreement and seek any other remedies available to it under law or equity. Notwithstanding the foregoing, in
the case of a breach in the payment for Products (not in reasonable dispute by DM), MM shall have only five (5) days after receipt of
notice to cure such failure, provided, that, DM will only be afforded a maximum of two (2) opportunities to cure payment defaults during
each calendar year of the term of this Agreement.

 

2.
In addition, if either Party shall file a voluntary petition in bankruptcy, be declared bankrupt, make an assignment for the benefit
of creditors, or suffer the appointment of a receiver or trustee of its assets or is declared insolvent, that party shall be in breach
of a material obligation of this Agreement, and the non- breaching Party may immediately terminate this Agreement upon written notice
to the breaching Party.

 

3.
Except for Section VI(5) below, nothing contained herein shall be deemed to limit either Party’s right to obtain damages or
equitable relief if either Party shall breach its obligations under this Agreement. All remedies shall be cumulative and are intended
to be, and shall be non-exclusive.

 

4.
Subject to Section VI(5) below, Tauriga may terminate this Agreement without cause, in its sole discretion, at any time upon sixty
(60) days advanced written notice to DM.

 

5.
Payout.

 

VII.
Dr L. AS AN INDEPENDENT CONTRACTOR. DM and Tauriga shall remain independent contractors and nothing herein shall be interpreted as
the parties hereto acting in concert or as joint venturers or partners. Except as specifically set forth herein, DM and Tauriga do not
convey to each other any property interest in the other’s corporate name, Trademarks or intellectual property. DM has not paid
nor agreed to pay any fee or other consideration for the rights conferred on it hereby, and agrees that it is not a franchisee within
the meaning of, and hereby expressly waives, to the fullest extent permitted by law, the benefits of and any claim under, any statute
or rule regulating franchises, distribution agreements or similar matters, or any so- called franchisee or distributor protection, or
business opportunity or dealership, laws.

 

VIII.
ASSIGNMENT. This Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of each party.
This Agreement is not assignable by either party without the prior express written consent of the other party, and any purported assignment
without such consent shall be null and void. Notwithstanding the foregoing, DM may assign this Agreement to a subsidiary of or other
affiliated entity in common control with DM without Tauriga’s consent upon written notice to Tauriga of such assignment, so long
as DM remains primarily liable for its obligations.

 

    	 

     

    

 

IX.
INDEMNIFICATION

 

1.
Dr. L shall indemnify, hold harmless and defend Tauriga, its affiliates and their respective officers, directors and employees from
any and all loss, liability, claim, damage, including but not limited to, claims of injury or death to person or damage to property,
and expenses (including reasonable attorney’s fees) which they, or any of them, may suffer or incur as a result or arising out
of the distribution or other activities of Dr. L under this Agreement including any intentional or negligent act/or omission to act by
Dr. L or any of its employees, agents officers or directors.

 

2.
Tauriga shall indemnify, hold harmless and defend DM, its affiliates and their respective officers, directors and employees from
any and all loss, liability, claim, damage, including but not limited to, claims of injury or death to person or damage to property,
and expenses (including reasonable attorney’s fees) which they, or any of them, may suffer or incur as a result or arising out
of the breach of any representation or obligation under this Agreement, and/or with respect to the Products, or the manufacturing, distribution
or other activities of Tauriga under this Agreement, including any intentional or negligent act/or omission to act by Tauriga or any
of its employees, agents, officer or directors.

 

3.
In any claim for indemnification under this Agreement, the party seeking indemnification (the “Indemnitee”) shall
give written notice to the other party against which such indemnification is sought (the “Indemnitor”) with reasonable
promptness after notice of any claim or suit involving, or which could involve, an indemnifiable claim under this Agreement. Notwithstanding
anything to the contrary provided in this Agreement, in any action in which such third party claims are asserted against the Indemnitee
(whether or not such claim is covered by insurance), the Indemnitee shall assert his, her or its right of indemnification against the
Indemnitor in that action, by whatever procedural options are available to the Indemnitee. If the Indemnitor has acknowledged in writing
its obligation to indemnify the Indemnitee in respect of third-party claim, the Indemnitee shall not settle or otherwise compromise such
claim without the prior written consent of the Indemnitor, which consent shall not be unreasonably withheld, unless this condition violates
the provisions of the Indemnitor’s liability insurance policy. The parties shall cooperate with one another in the defense of any
indemnifiable claim.

 

X.
INSURANCE. Tauriga maintains a product Liability Insurance Policy of $10,000,000 as of March 1, 2021

 

XI.
AUTHORITY. The undersigned persons executing this Agreement hereby certify that they are duly authorized and empowered by the governing
board of their respective company or corporation, and the articles and bylaws and/or operating agreement, as applicable, thereof, to
execute and deliver this Agreement.

 

XII.
FORCE MAJEURE

 

1.
A party’s obligation hereunder shall be suspended if such party is prevented from performing its obligations as a result of
fire, flood, explosion, accident, breakdown of machinery, product tampering by third parties, governmental acts, laws or regulations
(other than government action in response to public health violations by such party), war, terrorism, labor difficulties, any act of
God or any other cause not within such party’s control, which, by the exercise of reasonable due diligence, such party is not able
to avoid or overcome within a reasonable period of time (each, a “Force Majeure”).

 

2.
If Dr. L is the party that is unable to perform its obligations under this Agreement during the event of Force Majeure, upon the
occurrence of a Force Majeure event, DM shall assess in good faith, the projected duration of the Force Majeure event. If DM reasonably
anticipates the duration will be sixty (60) days or less, DM will notify Tauriga in writing of the anticipated duration, and Tauriga
may distribute its products through another distribution channel

 

    	 

     

    

 

3.
Notwithstanding any other provision of this Agreement, if a Force Majeure event continues for more than ninety (90) days, the party
whose performance is not impaired by such Force Majeure event may terminate this Agreement upon written notice to the other party, and
such termination shall be with cause.

 

XIII.
WAIVER. Failure of either party at any time to require performance by the other party of any provision of this agreement shall in
no way affect the full right to require such performance at any time thereafter. The waiver of either party to any provision of this
Agreement shall not be taken or held to be a waiver of any succeeding breach of such provisions or as a waiver of the provision itself.

 

XIV.
GOVERNING LAW; JURISDICTION. The parties agree that this Agreement shall be governed by, construed, and enforced in accordance with
the laws of the State of New York, without regard to principles of conflicts of laws. EACH OF THE PARTIES CONSENTS THAT ANY LEGAL ACTION
OR PROCEEDING AGAINST IT UNDER, ARISING OUT OF OR IN ANY MANNER RELATING TO THIS AGREEMENT, SHALL BE BROUGHT EXCLUSIVELY IN ANY COURT
OF THE STATE OF NEW YORK OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK, IN EACH CASE, IN THE COUNTY OF
NEW YORK. EACH OF THE PARTIES EXPRESSLY AND IRREVOCABLY CONSENTS AND SUBMITS TO THE PERSONAL JURISDICTION OF ANY OF SUCH COURTS IN ANY
SUCH ACTION OR PROCEEDINGS. EACH OF THE PARTIES AGREES THAT PERSONAL JURISDICTION OVER IT MAY BE OBTAINED BY THE DELIVERY OF A SUMMONS
(POSTAGE PREPAID) IN ACCORDANCE WITH THE PROVISIONS OF SECTION XX OF THIS AGREEMENT. ASSUMING DELIVERY OF THE SUMMONS IN ACCORDANCE WITH
THE PROVISIONS OF SECTION 19 OF THIS AGREEMENT, EACH OF THE PARTIES HEREBY EXPRESSLY AND IRREVOCABLY WAIVES ANY ALLEGED LACK OF PERSONAL
JURISDICTION, IMPROPER VENUE OF FORUM NON CONVENIENS OR ANY SIMILAR BASIS. EACH PARTY WAIVES TRIAL BY JURY IN ANY PROCEEDING HEREUNDER.

 

XV.
ARBITRATION. All disputes under this Agreement that cannot be resolved by the parties shall be submitted to arbitration under the
rules and regulations of the American Arbitration Association. Either party may invoke this paragraph after providing thirty (30) days’
written notice to the other party. All costs of arbitration shall be divided equally between the parties. Any award may be enforced by
a court of law.

 

XVI.
PRESS RELEASES. Dr. L acknowledges that Tauriga may be required to issue press releases from time to time as a reporting company
subject to the requirements of the Securities Exchange Act of 1934 Act (the “34 Act”) regarding material events relating
to any matter directly or indirectly pertaining to the Agreement, the results therefrom and/or the course of conduct of the Parties relating
thereto. In this regard, Tauriga acknowledges and agrees that it shall not issue any press release referring, directly or indirectly,
to the Agreement, DM and/or any of its affiliates, without the prior written approval of DM.

 

XVII.
ENTIRE AGREEMENT. This Agreement shall constitute the entire agreement between the parties and any prior understanding or representation
of any kind preceding the date of this agreement shall not be binding upon either party except to the extent incorporated in this Agreement.

 

XVIII.
MODIFICATION OF AGREEMENT. Any modification of this Agreement or additional obligation assumed by either party in connection with
this Agreement shall be binding only if evidenced in writing and signed by each party or an authorized representative of each party.

 

    	 

     

    

 

XIX.
EFFECT OF PARTIAL INVALIDITY. The invalidity of any portion of this Agreement will not and shall not be deemed to affect the validity
of any other provision. In the event that any provision of this Agreement is held to be invalid, the parties agree that the remaining
provisions shall be deemed to be in full force and effect as if they had been executed by both parties subsequent to the expungement
of the invalid provision.

 

XX.
NOTICES. Any notice provided for or concerning this Agreement shall be in writing and shall be deemed sufficiently given when sent
a nationally recognized overnight courier service to the persons and address as set forth below:

 

For
Dr. L or DM.: Dr. Craig Loucks

Orthopedic
Surgeon

145 Inverness Drive E., Ste # 220 Englewood, Colorado 80112

Attn:
Dr. Craig Loucks

 

For
Tauriga: Tauriga Sciences Inc.

4
Nancy Court, Suite # 4 Wappingers Falls, NY 12590 Attn: Seth M. Shaw, CEO

 

XXI.
PARAGRAPH HEADINGS. The titles to the paragraphs of this Agreement are solely for the convenience of the parties and shall not be
used to explain, modify, simplify, or aid in the interpretation of the provisions of this Agreement.

 

XXII.
COUNTERPARTS AND FAX SIGNATURES. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original,
and all such counterparts shall constitute a single instrument. The parties agree that a facsimile or digital signature of a party hereto
shall be deemed to be as legally effective and binding as a signed original; provided, however, any party providing a fax or digital
signature shall be required to promptly forward a signed original to any requesting party.

 

IN
WITNESS WHEREOF, the parties hereto have duly executed this Agreement the day and year first above written.

Tauriga Sciences Inc.

 

	By:		 
	Name:	Seth
    M. Shaw	 
	Title:	Chief
    Executive Officer,	 

 

Date Effective: May 15, 2021 

 

Dr.
Craig Loucks

	By:	 	 
	Name:	Dr.
    Craig Loucks	 
	Title:	Medical
    Advisor	 

 

    	 

     

    

 

EXHIBIT
AExhibit 10.27

 

 

This
Consulting Agreement (the “Agreement”) is made and entered into to be effective as June 14, 2021 (the “Effective Date”)
between Mayer & Associates or its designees with offices located at NY NY (the “Consultant”) and Tauriga Sciences (TAUG)
or any surviving company (‘‘the Company”). The Company and the Consultant are sometimes referred to individually, as
a “Party” and collectively, as the “Parties.”

 

WHEREAS,
the Consultant has the professional business expertise to assist the Company, and the Consultant is offering its services
as a consultant to the Company; and

 

WHEREAS
the Company desires to retain the Consultant as an independent consultant to provide services to the Company pursuant to the terms
of this Agreement, and.

 

NOW,
THEREFORE, in consideration of the premises and promises, warranties and representations herein contained, it is agreed as follows:

 

 

	1.	DUTIES AND SERVICES. The
    Company hereby engages the Consultant, and the Consultant hereby accepts engagement as a consultant for an initial period of 12 months.
    Agreement is cancelable after 6 months It is understood and agreed, and it is the express intention of the Parties to this Agreement,
    that the Consultant is an independent contractor, and not an employee or agent of the Company for any purpose whatsoever. Consultant
    shall perform all duties and obligations to the extent reasonably required in the conduct of its business with the Company, to place
    at the disposal of the Company Consultant’s judgment and experience and to provide business development services to the Company
    including, but not limited, to, the following:
	 	 	 
	 	(i)	To
    Provide the Company with Opportunities relating to the world of Professional Sports, with respect to its Products and Product Lines.
    This includes but is not limited to: introductions to professional sports leagues, celebrity (professional athletes) influencers/brand
    ambassadors/brand liaison(s), research and development opportunities, and most notably: working relationship with NFL Hall of Famer,
    Ray Lewis, to help the Company establish itself in the Professional Sports market segment. Lastly, a mutually agreed upon press release
    (disclosing Ray Lewis’ “best efforts” assistance in both: helping the Company build brand awareness and helping
    the Company penetrate the world of Professional Sports etc. etc.)
	 	(ii)	Periodic
    small Events to host the Company and a diversified group of high-profile contacts and relationships.
	 	(iii)	To
    include but not limited too Social Media exposure, Podcasts, backing of various elements from Professional Sports etc
	 	(iv)	Assist
    the Company in advising of potential merger partners and developing corporate partnering relationships.

 

It
is understood by the Parties, however, that the Consultant will maintain Consultant’s own business in addition to providing services
to the Company. The Consultant agrees to promptly perform all services required of the Consultant hereunder in an efficient, professional,
trustworthy, and businesslike manner. In such capacity, Consultant will utilize only materials, reports, financial information, or other
documentation that is approved in writing in advance by the Company. It is acknowledged and agreed by the Company that Consultant carries
no professional licenses and is not rendering legal advice or performing accounting services, nor acting
as an investment advisor or brokerage/dealer within the meaning of the applicable state and federal securities laws. Consultant
shall not engage in any actions that would be considered “fundraising” will not solicit investments on behalf of the Company
in any way and will in no way be compensated for any fundraising activities conducted by the Company.

 

    	1

     

    

 

	2. 	CONSULTING SERVICES & COMPENSATION. The Consultant will be retained as a Consultant and independent contractor for the Company. For services rendered hereunder, the Consultant shall receive as consideration for the Duties and Services set forth in Section 1 above:

 

	 	a.	CONTRACTUALLY
    OWED at Signing: Upon execution of this Agreement the company shall pay $75,000 USD and issue 2,200,000 common shares.
	 	b.	CONTRACTUALLY
    OWED at Signing: Exactly 90 days after execution of this Agreement, the Company shall make another payment of $75,000 USD and issue
    an additional 1,300,000 common shares.
	 	 	 
	 	Additional
    bonuses to be discussed upon significant sales Milestones and Partnerships with Professional sports.
	 	 	 
	 	c.	NOT
    CONTRACTUALLY OWED at Signing: Exactly180 days after execution of this Agreement, a final $75,000 USD payment (which is contingent
    upon approval by Tauriga Sciences Inc.’s Board of Directors).

 

There
will be separate amendments for additional duties and events.

 

	3.	 EXPENSES. In addition to the compensation in Section 2 above, the Company agrees to reimburse the Consultant, from time to time, for reasonable out-of-pocket expenses incurred by the Consultant in connection with its activities under this agreement, provided, however the Consultant shall not incur any expense more than $1,000 or $2,500 cumulative nickel dime items without prior written company consent. These expenses include but are not limited to airfare, hotel lodging, meals, transportation, outside consultants, printing, and overnight express mail.
	 	 
	4. 	CONFIDENTIALITY. All knowledge and information of a proprietary and confidential nature relating to the Company which the Consultant obtains during the Consulting period, from the Company or the Company’s employees, agents or Consultants shall be for all purposes regarded and treated as strictly confidential for so long as such information remains proprietary and confidential and shall be held in trust by the Consultant solely for the Company’s benefit and use and shall not be directly or indirectly disclosed by the Consultant to any person without the prior written consent of the Company, which consent may be withheld by the Company in its sole discretion.
	 	 
	5. 	INDEPENDENT CONTRACTOR STATUS. Consultant understands that since the Consultant is not an employee of the Company, the Company will not withhold income taxes or pay any employee taxes on its behalf, nor will it receive any fringe benefits. The Consultant shall not have any authority to assume or create any obligations, express or implied, on behalf of the Company and shall have no authority to represent the Company as agent, employee or in any other capacity that as herein provided. The Consultant does hereby indemnify and hold harmless the Company from and against any and all claims, liabilities, demands, losses or expenses incurred by the Company if (1) the Consultant fails to pay any applicable income and/or employment taxes (including interest or penalties of whatever nature), in any amount, relating to the Consultant’s rendering of consulting services to the Company, including any attorney’s fees or costs to the prevailing Party to enforce this indemnity or (2) Consultant takes any action or fails to take any action in accordance with the company’s instructions. The Consultant shall also be responsible for obtaining workers’ compensation insurance coverage and agrees to indemnify, defend, and hold the Company harmless of and from any and all claims arising out of any injury, disability or death of the Consultant.

 

    	2

     

    

 

 

	6. 	REPRESENATIONS AND WARRANTS. For purposes of this Agreement and the Shares being issued as consideration, the Consultant represents and warrants as follows:

 

	 	a.	The
    Consultant (i) has adequate means of providing for the Consultant’s current needs and possible personal contingencies, (ii)
    has no need for liquidity in this investment, (iii) can bear the substantial economic risks of an investment in the Shares for an
    indefinite period, (iv) at the present time, can afford a complete loss of such investment, and (v) is an
    “accredited investor” as defined in the Securities Act of 1933, as amended.
	 	 	 
	 	b.	The
    Consultant does not have a preexisting personal or business relationship with the Company or any of its directors or executive officers,
    or by reason of any business financial expertise or the business or financial experience of any professional advisors who are unaffiliated
    with and who are compensated by the Company or any affiliate or selling agent of the Company, directly or indirectly, could be reasonably
    assumed to have the capacity to protect the Consultant’s interests in connection with the investment in the Company.
	 	 	 
	 	c.	The
    Consultant is aware that:
	 	 	 	 
	 	 	i.	The
    Shares are not transferable under this Agreement and applicable securities laws; and are restricted securities that may only be sold
    if registered in an effective registration statement or under an exemption from registration;
    and
	 	 	 	 
	 	 	ii.	The
    Articles of Incorporation and Bylaws of the Company contain provisions that limit or eliminate the personal liability of the officers,
    directors and agents of the Company and indemnify such Parties for certain damages relating to the Company, including damages in
    connection with the Shares and the good-faith management and operation of the Company.
	 	 	 	 
	 	d.	The
    Consultant acknowledges that the Shares (other than the Shares to be registered on Form S-8), which are issuable under this Agreement
    are not currently registered under the Securities Act of 1933, as amended (the “Act”) nor does the Company have any obligation
    to register the Shares (other than the S-8 Shares) under the Act.
	 	 	 
	 	e.	The
    Consultant has not been furnished any offering literature and has not been otherwise solicited by the Company.
	 	 	 
	 	f.	The
    Company and its officers, directors and agents have answered all inquiries that the Consultant has made of them concerning the Company
    or any other matters relating to the formation, operation and proposed operation of the Company and the offering and sale of the
    Shares.
	 	 	 
	 	g.	The
    Consultant, if a corporation, partnership, trust, or other entity, is duly organized and in good standing in the state or country
    of its incorporation and is authorized and otherwise duly qualified to purchase and hold the Shares. Such entity has its principal
    place for business as set forth on the signature page hereof and has not been formed for the specific purpose of acquiring the Shares
    unless all its equity owners qualify asaccredited individual investors.

 

 

    	3

     

    

 

	 	h.	All
    information that the Consultant has provided to the Company concerning the Consultant, the Consultant’s financial position
    and the Consultant’s knowledge of financial and business matters, or, in the case of a corporation, partnership, trust or other
    entity, the knowledge of financial and business matters of the person making the investment decision on behalf of such entity, including
    all information contained herein, is correct and complete as of the date set forth at the end hereof and may be relied upon, and
    if there should be any material adverse change in such information prior to this subscription being accepted, the Consultant will
    immediately provide the Company with such information.
	 	 	 	 
	 	i.	The
    Consultant certifies, under penalties of perjury (i) that the taxpayer identification number shown on the signature page of this
    Consulting Agreement is true, correct, and complete, and (ii)that the Consultant is not subject to backup withholding as a result
    of a failure to report all interest or dividends, or because the Internal Revenue Service has notified the Consultant that
    the Consultant is no longer subject to backup withholding.
	 	 	 
	 	 	 
	 	j.	In
    rendering the services hereunder and in connection with the Shares, the Consultant agrees to comply with all applicable federal and
    state securities laws, the rules, and regulations thereunder, the rules and regulations of any exchange or quotation service on which
    the Company’s securities are listed ‘and the rules and regulations of the National Association of Securities Dealers,
    Inc.

 

	7. 	TERMINATION. Either Party may terminate this Agreement at any time with or without cause by giving thirty (30) days written notice to the other Party. Should the Consultant default in the performance of this Agreement or materially breach any of its provisions, the Company may, in its sole discretion, terminate this Agreement immediately upon written notice to the Consultant. If this agreement is terminated for any reason, Consultant shall have no right to any shares that have not vested pursuant to Section 2 of this Agreement as of the termination date
	 	 
	8. 	NO THIRD-PARTY RIGHTS. The Parties warrant and represent that they are authorized to enter into this Agreement and that no third parties, other than the Parties hereto, have any interest in any of the services or the Warrant contemplated hereby.
	 	 
	9.	ABSENCE OF WARRANTIES AND REPRESENTATIONS. Each
Party hereto acknowledges that they have signed this Agreement without having relied upon or being induced by any agreement, warranty
or representation of fact or opinion of any person not expressly set forth herein. All representations and warranties of either Party
contained herein shall survive its signing and delivery.

 

 

    	4

     

    

 

 

 

	10. 	GOVERNING LAW. This Agreement shall be governed by and construed in accordance with the law of the State of New York.
	 	 
	11. 	ATTORNEY’S FEES. In the event of any controversy, claim or dispute between the Parties hereto, arising out of or in any manner relating to this Agreement, including an attempt to rescind, or set aside, the prevailing Party in any action brought to settle such controversy, claim or dispute shall be entitled to recover reasonable attorney’s fees and costs.

 

    	5

     

    

 

 

	12. 	ARBITRATION. Any controversy between the Parties regarding the construction or application of this Agreement, any claim arising out of this Agreement or its breach, shall be submitted to arbitration in Nevada before one arbitrator in accordance with the Commercial Arbitration Rules of the American Arbitration Association, upon the written request of one Party after service of that request on the other Party. The cost of arbitration shall be borne by the losing Party. The arbitrator is also authorized to award attorney’s fees to the prevailing Party.
	 	 
	13. 	VALIDITY. If any paragraph, sentence, term, or provision hereof shall be held to be invalid or unenforceable for any reason, such invalidity or unenforceability shall not affect the validity enforceability of any other paragraph, sentence, term and provision hereof. To the extent required, any paragraph, sentence, term or provision of this Agreement may be modified by the Parties hereto by written amendment to preserve its validity.
	 	 
	14.	ON-DISCLOSURE OF TERMS. The terms of this Agreement
shall be confidential, no Party, representative, attorney, or family shall reveal its contents to a 3rd party except as required
by law or as necessary to comply with preexisting contractual commitments.

 

    	6

     

    

 

 

	15. 	ENTIRE AGREEMENT. This Agreement contains the entire understanding of the Parties and cannot be altered or amended except by an amendment duly executed by all Parties hereto. This Agreement shall be binding upon and inure to the benefit of the successors, assigns and personal representatives of the Parties.

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Consulting Agreement effective as of the date first written above.

 

	By:		 	
	Name:	Benjamin
    Mayer	 	Name:	Seth
    Shaw
	Mayer
    & Associates LLC	 	Tauriga
    Sciences Inc.
	Consultant	 	Chief
    Executive Officer
	 	 	 	 	                                 
	 	 	 	Effect Date: June 15, 2021

 

    	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]